Our History
In 1988, Mitch Singer and Mort Rezack founded PL Developments with the ambitious dream of bringing a higher level of service to the private label OTC industry.
With a little luck and a lot of hard work, Mitch and Mort obtained their first retail client by the end of year one. Their fresh, customer-focused approach and unwavering commitment to quality, paved the way for the next decade of steady growth.
Sadly, in 1998, Mort passed away. Mitch lost his long-time friend and fervent business partner. During this difficult time, Mitch assumed 100% ownership of PL Developments and saw this as a way to carry on Mort’s legacy. Mitch was more determined than ever to grow PLD to a company that Mort would be proud of.
By 2002, PLD was operating in a 55,000 sq. ft. facility. By 2007, PLD had outgrown the facility and moved into a 200,000 sq. ft. facility in Westbury, NY. This is the current, state-of-the-art finished dose packaging center for PLD.
In 2008, PLD marked a significant achievement with the acquisition of an 85,000 sq. ft. solid dose manufacturing facility. PLD’s capabilities were more diverse than ever and their products were now on the shelves of virtually every major retailer in the U.S.
In 2013, PLD made a true splash by acquiring Aaron Industries Liquid OTC pharmaceuticals. For the first time in history, PLD was offering the full range of solid and liquid dose health remedies, as well as numerous first aid items. Shortly after, PLD further expanded its portfolio to include health care items, as well beauty care products.
Over the next few years PLD continued to grow and in 2019 acquired Teva Pharmaceuticals’ U.S. store-brand drug portfolio. This major acquisition included a full line of NRT gum products and a range of other OTC goods to support PLD’s robust product pipeline, including more than 40 approved and pending ANDAs — one of which was the first-to-market store brand of Abreva® (Docosanol 10%) cold sore cream.
Our quality products would be nothing without our quality people. It’s a belief I’ve held since the very beginning and has been an integral part of our success.
— Mitch Singer, Founder, PL Developments
Today, PLD is committed to providing a solution for every health and beauty care aisle in retail stores.
From conservative beginnings, PLD has evolved into a position of a trusted industry leader, partnering with major retailers nationwide. To effectively serve their diverse clientele, PLD maintains state-of-the-art facilities and employs industry best practice from quality to creative services. And, proudly, Mitch Singer is still passionately at the helm of PL Developments— walking the hallways, visiting each department, or just popping in for a laugh or two. A true “family business,” Mitch’s wife, Linda Singer, serves as Executive VP of Creative Services. Their sons, Evan and Adam Singer, serve as President and Chief Operating Officer, respectively.
Mitch, along with his family — and extended family of 1600+ employees — ensure every PLD customer is given the level of service and dedication that was granted to their very first retail customer.
1988
PLD Founded by Mitch Singer and Mort Rezack.
1989
PLD acquires first retail client.
1998
Mitch Singer assumes 100% ownership of PLD.
2002
PLD enters new 55,000 sq. ft. facility in Farmingdale, NY.
2004
PLD begins shipping the world’s first private label OTC ibuprofen softgels.
2007
PLD enters new 200,000 sq. ft. facility in Westbury, NY.
2008
PLD acquires 85,000 sq. ft. solid dose manufacturing facility in Miami, FL.
2009
PLD acquires first ANDA (Ibuprofen 200 mg) to manufacture in Miami, FL.
2013
PLD acquired Aaron Industries Liquid OTC pharmacueticals.
2014
PLD moves Corporate Headquarters to a new 105,000 sq. ft. facility, with 65,000 sq. ft. serving as the state-of-the-art northeast distribution center.
2014
PLD expands portfolio to include additional health and beauty care items.
2017
PLD adds 200,000 sq. ft. rail-spur facility in South Carolina.
2019
PLD acquires Teva Pharmaceuticals’ U.S. store-brand drug portfolio, growing its FDA-approved ANDA offerings and high-value NRT line. As part of the acquisition, PLD obtains the only FDA-approved NRT chewing gum operation in the U.S.
2020
PLD partners with Amneal to launch the first store brand of Diclofenac Sodium Topical Gel 1%, the compare-to of Voltaren® arthritis pain relief gel.
2023
PLD launches gummy manufacturing, adding multi-line, starchless gummy production to its Copiague, NY facility.